# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated...
Stifel analyst Alex Thompson initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Targe...
Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and raises the price targe...
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August ...
Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $173 price target.
Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024